J. Cancer Mol. 4:
37-45, 2008
[Review Article]
Anti-Angiogenic Therapeutic Drugs for Treatment
of Human Cancer
Han-Chung Wu, Chia-Ting Huang, and De-Kuan Chang
Institute of Cellular and Organismic Biology, Academia
Sinica, Taipei, Taiwan
Abstract:
One of the proposed benefits of targeted therapies is reduced toxicity
and improved quality of life.
The
approval of a new broad family of molecularly targeted anticancer drugs
represents one of the most significant recent advances in clinical
oncology. The growth of solid tumors is dependent on their capacity to
acquire a blood supply. Much effort has been directed towards the
development of drugs that disrupt or normalize this process for cancer
therapy.
Some tumors also contain vasculogenic mimicry channels consisting of
cancer cells and their extracellular matrix. In solid tumors,
vasculogenic mimicry
has been found to be strongly correlated with advanced-stage disease and
poor outcome.
In this review article, we
summarize the clinical use of small molecules and therapeutic antibodies
as
angiogenesis inhibitors and their
toxic side effects.
We discuss
vasculogenic mimicry of solid tumors and describe strategies for
identifying putative tumor vascular targets. We end by
discussing the future prospects for
the clinical use of vascular targeting in treatment of cancer.
(Keywords: angiogenesis; anti-angiogenic
therapy; vasculogenic mimicry; toxicity)
_________________________________________________________________________________________________
Received 3/30/08; Revised 5/9/08; Accepted 5/12/08.
1.
Correspondence:
Dr. Han-Chung Wu, Institute of Cellular and Organismic Biology, Academia
Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei 11529,
Taiwan. Phone: 886-2-27899528.
E-mail: hcw0928@gate.sinica.edu.tw
2. Abbreviations:
MTD, maximum
tolerated dose; LVEF, left ventricular ejection fraction; MAb,
monoclonal antibody;
CEPs, circulating endothelial progenitor cells; CECs, circulating
endothelial cells; AMD, age-related wet macular degeneration;
CML, chronic myelogeneous
leukemia; TKI, tyrosine kinase inhibitor; RCC, renal cell carcinoma;
NSCLC, non-small
cell lung cancer;
ECM, extracellular
matrix; PAS staining,
periodic acid schiff staining.
Hyperlink to Full Text [PDF (884
KB)]
|
